203 related articles for article (PubMed ID: 32594283)
1. Patient Characteristics and Treatment Patterns among Medicare Beneficiaries Initiating PCSK9 Inhibitor Therapy.
Feng X; Berklein F; Rane PB; Habib M; Lin PJ
Cardiovasc Drugs Ther; 2021 Oct; 35(5):965-973. PubMed ID: 32594283
[TBL] [Abstract][Full Text] [Related]
2. Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors.
Hines DM; Rane P; Patel J; Harrison DJ; Wade RL
Vasc Health Risk Manag; 2018; 14():409-418. PubMed ID: 30573963
[TBL] [Abstract][Full Text] [Related]
3. Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol-Lowering Therapies Among Medicare Beneficiaries: An Analysis From the Medicare Part D Database.
Sumarsono A; Lalani HS; Vaduganathan M; Navar AM; Fonarow GC; Das SR; Pandey A
JAMA Cardiol; 2021 Jan; 6(1):92-96. PubMed ID: 32902560
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with time to initiation of a PCSK9 inhibitor after hospital discharge for acute myocardial infarction.
McKinley EC; Bittner VA; Brown TM; Chen L; Colantonio LD; Exter J; Orroth KK; Reading SR; Rosenson RS; Muntner P
J Clin Lipidol; 2022; 16(1):75-82. PubMed ID: 34848176
[TBL] [Abstract][Full Text] [Related]
5. Use of negative control outcomes to assess the comparability of patients initiating lipid-lowering therapies.
Levintow SN; Orroth KK; Breskin A; Park AS; Flores-Arredondo JH; Dluzniewski P; Navar AM; Sørensen HT; Brookhart MA
Pharmacoepidemiol Drug Saf; 2022 Apr; 31(4):383-392. PubMed ID: 34894377
[TBL] [Abstract][Full Text] [Related]
6. PCSK9 Inhibitors and Ezetimibe Monotherapy in Patients Not Receiving Statins: A Meta-Analysis of Randomized Trials.
Benhuri B; Ueyama H; Takagi H; Briasoulis A; Kuno T
Curr Vasc Pharmacol; 2021; 19(4):390-397. PubMed ID: 32767943
[TBL] [Abstract][Full Text] [Related]
7. Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease.
Mallya UG; Boklage SH; Koren A; Delea TE; Mullins CD
Pharmacoeconomics; 2018 Jan; 36(1):115-126. PubMed ID: 29181773
[TBL] [Abstract][Full Text] [Related]
8. Race/ethnic and sex differences in the initiation of non-statin lipid-lowering medication following myocardial infarction.
Colvin CL; Poudel B; Bress AP; Derington CG; King JB; Wen Y; Chen L; Bittner V; Brown TM; Monda KL; Mues KE; Rosenson RS; Jackson EA; Muntner P; Colantonio LD
J Clin Lipidol; 2021; 15(5):665-673. PubMed ID: 34452823
[TBL] [Abstract][Full Text] [Related]
9. A Retrospective Chart Review Evaluating Efficacy, Tolerability, and Cost of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Older Adults.
Davis LE; Pogge EK
High Blood Press Cardiovasc Prev; 2020 Aug; 27(4):331-338. PubMed ID: 32651891
[TBL] [Abstract][Full Text] [Related]
10. Persistence and Adherence to PCSK9 Inhibitor Monoclonal Antibodies Versus Ezetimibe in Real-World Settings.
Muntner P; Ghazi L; Jones J; Dhalwani N; Poudel B; Wen Y; Chen L; Wang Z; Bittner V; Kalich B; Farkouh ME; Woodward M; Colantonio LD; Rosenson RS
Adv Ther; 2024 Jun; 41(6):2399-2413. PubMed ID: 38691317
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
[TBL] [Abstract][Full Text] [Related]
12. Use of Low-Density Lipoprotein-Lowering Therapies Before and After PCSK9 Inhibitor Initiation.
Rymer JA; Mues KE; Monda KL; Bratton EW; Wirtz HS; Okerson T; Overman RA; Brookhart MA; Muntner P; Wang TY
J Am Heart Assoc; 2020 May; 9(9):e014347. PubMed ID: 32326795
[TBL] [Abstract][Full Text] [Related]
13. Incremental net benefit of lipid-lowering therapy with PCSK9 inhibitors: a systematic review and meta-analysis of cost-utility studies.
Bagepally BS; Sasidharan A
Eur J Clin Pharmacol; 2022 Mar; 78(3):351-363. PubMed ID: 34708270
[TBL] [Abstract][Full Text] [Related]
14. The need for PCSK9 inhibitors and associated treatment costs according to the 2019 ESC dyslipidaemia guidelines vs. the risk-based allocation algorithm of the 2017 ESC consensus statement: a simulation study in a contemporary CAD cohort.
Blaum C; Seiffert M; Goßling A; Kröger F; Bay B; Lorenz T; Braetz J; Graef A; Zeller T; Schnabel R; Clemmensen P; Westermann D; Blankenberg S; Brunner FJ; Waldeyer C
Eur J Prev Cardiol; 2021 Mar; 28(1):47-56. PubMed ID: 33580772
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics and lipid lowering treatment of patients initiated on proprotein convertase subtilisin-kexin type 9 inhibitors: a nationwide cohort study.
Jensen JS; Weeke PE; Bang LE; Høfsten DE; Ripa MS; Schjerning AM; Theilade JE; Køber LV; Gislason GH; Pallisgaard J
BMJ Open; 2019 Apr; 9(4):e022702. PubMed ID: 30940751
[TBL] [Abstract][Full Text] [Related]
16. Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy.
Navar AM; Taylor B; Mulder H; Fievitz E; Monda KL; Fievitz A; Maya JF; López JAG; Peterson ED
JAMA Cardiol; 2017 Nov; 2(11):1217-1225. PubMed ID: 28973087
[TBL] [Abstract][Full Text] [Related]
17. Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID): A Randomized Clinical Trial.
Shah NN; Ghazi L; Yamamoto Y; Kumar S; Martin M; Simonov M; Riello Iii RJ; Faridi KF; Ahmad T; Wilson FP; Desai NR
Circ Cardiovasc Qual Outcomes; 2024 May; 17(5):e010335. PubMed ID: 38634282
[TBL] [Abstract][Full Text] [Related]
18. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial.
Arrieta A; Hong JC; Khera R; Virani SS; Krumholz HM; Nasir K
JAMA Cardiol; 2017 Dec; 2(12):1369-1374. PubMed ID: 29049467
[TBL] [Abstract][Full Text] [Related]
19. Trends and Factors Associated With Insurer Approval of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Prescriptions.
Doshi JA; Li P; Puckett JT; Pettit AR; Raman S; Parmacek MS; Rader DJ
Value Health; 2020 Feb; 23(2):209-216. PubMed ID: 32113626
[TBL] [Abstract][Full Text] [Related]
20. Uptake of non-statin lipid-lowering therapies for secondary prevention in community practice.
Bradley CK; Kolkailah AA; Shah NP; Page CB; Peterson ED; Navar AM
J Clin Lipidol; 2023; 17(3):412-414. PubMed ID: 37029056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
